

1P-422-C025

Monoclonal Antibody to HLA-Class I Phycoerythrin (PE) conjugated (0.025 mg)

Clone: W6/32

Isotype: Mouse IgG2a

Specificity: The antibody W6/32 recognises MHC Class I molecules (MHC Class Ia) that are

expressed on the surface of all human nucleated cell types.

The antibody W6/32 is a valuable reagent for analysing variations in HLA class I expression in different disease states e.g. liver disease, muscular dystrophy,

inflammatory myopathy and other neuromuscular disorders.

This antibody W6/32 is also suitable as a positive control for HLA tissue typing and

crossmatching.

Regulatory Status: RUO

Immunogen: Membrane of human tonsil cells

Species Reactivity: Human, Non-Human Primates, Bovine, Feline (Cat)

Negative Species: Rabbit

Preparation: The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum

conditions. The conjugate is purified by size-exclusion chromatography.

Concentration: 0.1 mg/ml

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis.

Suggested working dilution is 1:50. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the

investigator.

Expiration: See vial label

Lot Number: See vial label

Background: HLA-class I major histocompatibility (MHC) antigens are intrinsic membrane

glycoproteins expressed on nucleated cells and noncovalently associated with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumour defence. Human HLA-class I antigens are represented by HLA-A,

HLA-B and HLA-C molecules.



PRODUCT DATA SHEET

References:

*Barnstable, C. J., et al. (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens - new tools for genetic analysis. Cell. 14: 9 - 20.

*Brodsky, F.M. et al. (1982): Evolution of HLA antigenic determinants: species cross reactions of monoclonal antibodies. Immunogenetics 15: 151-166.

*Neefjes, J.J. et al. (1986): A biochemical characterization of feline MHC products: unusually high expression of class II antigens on peripheral blood lymphocytes. Immunogenetics 23: 341-347.

*Stern, P. et al. (1987): Class I-like MHC molecules expressed by baboon placental synctiotrophoblast. Journal of Immunology. 138 (4): 1088 - 1091.

*Kievits F, Ivanyi P: Monomorphic anti-HLA monoclonal antibody (W6/32) recognizes polymorphic H-2 heavy-chain determinants exposed by association with bovine or human but not murine beta 2-microglobulin.Hum Immunol. 1987 Oct;20(2):115-26.

*Jacobsen, C. N. et al. (1993): Reactivities of 20 anti-human monclonal antibodies with leucocytes from ten different animal species. Vet. Immunopathol. 39: 461 - 466

*Shields MJ, Ribaudo RK: Mapping of the monoclonal antibody W6/32: sensitivity to the amino terminus of beta2-microglobulin. Tissue Antigens 1998 May;51(5):567-70.

*Ladasky JJ, Shum BP, Canavez F, Seuanez HN, Parham P: Residue 3 of beta2-microglobulin affects binding of class I MHC molecules by the W6/32 antibody. Immunogenetics. 1999 Apr;49(4):312-20.

*Tran TM, Ivanyi P, Hilgert I, Brdicka T, Pla M, Breur B, Flieger M, Ivaskova E, Horejsi V: The epitope recognized by pan-HLA class I-reactive monoclonal antibody W6/32 and its relationship to unusual stability of the HLA-B27/beta2-microglobulin complex. Immunogenetics. 2001 Aug;53(6):440-6. *Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED: Expression of

HLA-G in human cornea, an immune-privileged tissue. Hum Immunol. 2003 Nov;64(11):1039-44.

*And many other.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.